TD Asset Management Inc Acquires Shares of 66,906 Enliven Therapeutics, Inc. $ELVN

TD Asset Management Inc acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 66,906 shares of the company’s stock, valued at approximately $1,342,000.

A number of other institutional investors have also modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Enliven Therapeutics by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock valued at $428,000 after buying an additional 1,693 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Enliven Therapeutics by 4.9% during the 1st quarter. Rhumbline Advisers now owns 52,502 shares of the company’s stock valued at $1,033,000 after buying an additional 2,466 shares during the last quarter. KLP Kapitalforvaltning AS raised its stake in shares of Enliven Therapeutics by 58.1% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after buying an additional 2,500 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Enliven Therapeutics by 3,058.1% in the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock valued at $53,000 after purchasing an additional 2,630 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in shares of Enliven Therapeutics in the 1st quarter valued at about $60,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on ELVN. HC Wainwright lifted their price target on Enliven Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, July 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $41.20.

Insider Transactions at Enliven Therapeutics

In other news, CEO Samuel Kintz sold 12,500 shares of the business’s stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $21.33, for a total transaction of $266,625.00. Following the transaction, the chief executive officer directly owned 902,892 shares in the company, valued at $19,258,686.36. The trade was a 1.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Anish Patel sold 6,667 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $20.24, for a total value of $134,940.08. Following the transaction, the chief operating officer owned 283,308 shares in the company, valued at approximately $5,734,153.92. This represents a 2.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 103,234 shares of company stock worth $2,093,844 in the last ninety days. Insiders own 25.90% of the company’s stock.

Enliven Therapeutics Trading Down 3.3%

ELVN stock opened at $20.49 on Thursday. Enliven Therapeutics, Inc. has a 12-month low of $13.30 and a 12-month high of $29.78. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -10.25 and a beta of 0.85. The business’s 50-day moving average is $20.13 and its 200 day moving average is $19.63.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. As a group, equities analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.